Valuation: ALLOVIRPAR

Market Cap 49.21M 43.01M 39.68M 36.58M 68.94M 4.74B 70.48M 474M 187M 2.32B 185M 181M 7.99B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -60.37M -55.7M -51.35M -96.78M -6.65B -98.93M -666M -262M -3.26B -259M -254M -11.22B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-4.99%
Current month-55.35%
Current year-55.35%
3 years 4.3
Extreme 4.3
86.25
5 years 4.3
Extreme 4.3
607.43
10 years 4.3
Extreme 4.3
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -166M -154M -142M -267M -18.34B -273M -1.84B -722M -8.98B -715M -699M -30.92B -58.77M -51.36M -47.39M -43.68M -82.34M -5.66B -84.16M -566M -223M -2.77B -221M -216M -9.54B
Net Debt -157M -137M -126M -116M -219M -15.07B -224M -1.51B -593M -7.38B -588M -575M -25.41B -118M -103M -95.39M -87.93M -166M -11.39B -169M -1.14B -448M -5.58B -444M -434M -19.21B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
17/07/26 USD 4.380 -4.99% 10,944,041
16/07/26 USD 4.610 -4.36% 61,346
15/07/26 USD 4.820 +5.93% 74,362
14/07/26 USD 4.550 +2.94% 35,441
13/07/26 USD 4.420 -0.45% 68,023
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock